While the peptide and protein therapeutic market has developed significantly in the past
decades, delivery has limited their use. Although oral delivery is preferred, most are …

Lipid-based nanocarriers have gained much interest as carriers of drugs with poor oral
bioavailability because of their remarkable advantages like low toxicity, affordable scale-up …

The emerging field of precision medicine is rapidly growing, fostered by the advances in
genome mapping and molecular diagnosis. In general, the translation of these advances …

Peptides and proteins remain poorly bioavailable upon oral administration. One of the most
promising strategies to improve their oral delivery relies on their association with colloidal …

In 1990, the lipid nanoparticles were invented in the laboratories, the first patent filings took
place in 1991. The lipid nanoparticles were developed as alternative to traditional carriers …

Therapeutic peptides/proteins and protein-based antigens are chemically and structurally
labile compounds, which are almost exclusively administered by parenteral injections …

Solid lipid particulate systems such as solid lipid nanoparticles (SLN), lipid microparticles
(LM) and lipospheres have been sought as alternative carriers for therapeutic peptides …

The purpose of this expert review is to discuss the impact of nanotechnology in the treatment
of the major health threats including cancer, infections, metabolic diseases, autoimmune …

Solid lipid nanoparticles (SLN) have been reported to be an alternative system to emulsions,
liposomes, microparticles and their polymeric counterparts for various application routes …

This article is aimed to overview the lipid-based nanostructures designed so far for the oral
administration of peptides and proteins, and to analyze the influence of their composition …